• Atrium Therapeutics highlighted a pipeline of precision RNA medicines for cardiac disease, led by ATR1072 for PRKAG2 syndrome.
• ATR1072 is slated to enroll its first patient in a Phase 1/2 trial by end-2026, with initial proof-of-concept data targeted for 2H 2027.
• Preclinical data showed PRKAG2 mRNA reduction, with improvements in diastolic function and atrial signaling measures in a PRKAG2 mouse model.
• Monkey studies cited repeat-dose tolerability, no dose-limiting toxicity at the highest dose tested, no cardiac function effects across ECG and echo assessments.
• ATR1086 for PLN cardiomyopathy is in IND-enabling studies, with an IND filing targeted for 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.